Sintx Technologies (DB:1110) - Stock Price, News & Analysis

1110 Stock Overview

An advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States.

About the company

1110 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Revenue is forecast to grow 12.04% per year

Earnings have grown 5.6% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months

Does not have a meaningful market cap (€3M)

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

+ 3 more risks

Sintx Technologies, Inc. Competitors

MagForce

XTRA:MF6

€3.6m

Audientes

DB:AUG

€6.9m

elexxion

XTRA:E8X

€717.5k

aap Implantate

XTRA:AAQ1

€13.1m

Price History & Performance

Summary of all time highs, changes and price drops for Sintx Technologies
Historical stock prices
Current Share Price	US$13.00
52 Week High	US$300.00
52 Week Low	US$3.62
Beta	1.34
1 Month Change	-58.76%
3 Month Change	-40.91%
1 Year Change	-95.39%
3 Year Change	-99.95%
5 Year Change	-99.96%
Change since IPO	-100.00%

Recent updates

Shareholder Returns

	1110	DE Medical Equipment	DE Market
7D	0%	-2.4%	-3.1%
1Y	-95.4%	-2.2%	-0.5%

Return vs Industry: 1110 underperformed the German Medical Equipment industry which returned -2.2% over the past year.

Return vs Market: 1110 underperformed the German Market which returned -0.5% over the past year.

Price Volatility

Is 1110's price volatile compared to industry and market?
1110 volatility
1110 Average Weekly Movement	109.4%
Medical Equipment Industry Average Movement	4.5%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: 1110's share price has been volatile over the past 3 months.

Volatility Over Time: 1110's weekly volatility has increased from 50% to 109% over the past year.

About the Company

Founded	Employees	CEO	Website
1996	43	B. Bal	www.sintx.com

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation.

Sintx Technologies, Inc. Fundamentals Summary

How do Sintx Technologies's earnings and revenue compare to its market cap?
1110 fundamental statistics
Market cap	€2.77m
Earnings (TTM)	-€8.29m
Revenue (TTM)	€2.59m

1.1x

P/S Ratio

-0.3x

P/E Ratio

Is 1110 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1110 income statement (TTM)
Revenue	US$2.78m
Cost of Revenue	US$889.00k
Gross Profit	US$1.89m
Other Expenses	US$10.76m
Earnings	-US$8.88m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-14.47
Gross Margin	67.96%
Net Profit Margin	-319.93%
Debt/Equity Ratio	2.3%

How did 1110 perform over the long term?

See historical performance and comparison

1110 Stock Overview

Rewards

Risk Analysis

Sintx Technologies, Inc. Competitors

XTRA:MF6

€3.6m

DB:AUG

€6.9m

XTRA:E8X

€717.5k

XTRA:AAQ1

€13.1m

Price History & Performance

Recent News & Updates

Sintx Technologies Regains Compliance with Nasdaq Bid Price Requirement

Sintx Technologies Declares 1-for-200 Reverse Stock Split Effective May 28, 2024 to Bring it into Compliance with the Minimum Bid Price Requirements for Maintaining the Listing on the Nasdaq Capital Market

First quarter 2024 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2023)

Sintx Technologies Receives New Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Sintx Technologies, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$2.22 loss per share (vs US$54.67 loss in FY 2022)

Recent updates

Sintx Technologies Regains Compliance with Nasdaq Bid Price Requirement

Sintx Technologies Declares 1-for-200 Reverse Stock Split Effective May 28, 2024 to Bring it into Compliance with the Minimum Bid Price Requirements for Maintaining the Listing on the Nasdaq Capital Market

First quarter 2024 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2023)

Sintx Technologies Receives New Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Sintx Technologies, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$2.22 loss per share (vs US$54.67 loss in FY 2022)

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $1.030519 million.

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$11.02 loss in 3Q 2022)

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

SINTX Technologies Receives a Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Sintx Technologies, Inc. Receives Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$10.16 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$11.51 loss in 1Q 2022)

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sintx Technologies Receives Notice from the Listing Qualifications Staff of Nasdaq

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.095 loss in 3Q 2021)

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $4.7 million.

Sintx Technologies, Inc. Announces New Antibacterial Biomedical Patents and Expansion of Intellectual Property Portfolio

National Institutes of Health Announces Grant to Sintx Technologies for Development of 3D Printed Antimicrobial Trauma Device

Oxford Performance Materials and SINTX Technologies Collaboration Yields Major Breakthrough in Orthopedic & Dental Coatings

No longer forecast to breakeven

Second quarter 2022 earnings released: US$0.10 loss per share (vs US$0.089 loss in 2Q 2021)

Sintx Technologies, Inc. (NasdaqCM:SINT) acquired Technology Assessment And Transfer, Inc. for 0.76 million.

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.11 loss in 1Q 2021)

Insufficient new directors

Insufficient new directors

Full year 2021 earnings released: US$0.35 loss per share (vs US$1.01 loss in FY 2020)

No longer forecast to breakeven

Insufficient new directors

SINTX Technologies, Inc. Announces New Results on the Development of Manufacturing Technologies to Produce Fabrics Impregnated with SINTX Silicon Nitride, and the Antipathogenic Testing of These Fabrics

SINTX Technologies Receives A Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.095 loss per share (vs US$0.11 loss in 3Q 2020)

Sintx Technologies, Inc. Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY

First quarter 2021 earnings released: US$0.11 loss per share (vs US$1.35 loss in 1Q 2020)

SINTX Technologies Announces New Product Brand, FleX SN, For Antipathogenic and Biomedical Applications

SINTX Technologies Files Multiple New U.S. and International Patent Applications

Full year 2020 earnings released: US$1.01 loss per share (vs US$4.82 loss in FY 2019)

Sintx Technologies, Inc. Announces the Fabric Technology Shown to Inactivate Upon contact SARS-CoV-2, the Virus Causing the Covid-19 Pandemic

SINTX Technologies, Inc. Submits Master Access File to FDA for Silicon Nitride-Polymer Composite Material

O2TODAY and SINTX Technologies Enter Commercialization Agreement to Fight COVID-19

Sintx Technologies Enters into Patent License Agreement with O2 Design, Inc. to Commercialize Face Masks and Mask Filter

New 90-day high: €1.79

New 90-day low: €1.30

Revenue misses expectations

Third quarter 2020 earnings released: US$0.11 loss per share

SINTX Technologies and Iwatani Group Announce Agreement to Develop Antipathogenic Surfaces to Help Prevent Spread of the Common Flu, COVID-19, and Other Viral Diseases

SINTX Technologies, Inc. Develops New Mask Fabric with Silicon Nitride

SINTX Technologies Appoints Michael Marcroft as Vice President of Business Development

Sintx Technologies, Inc. Hires Don Bray as Vice President of Business Development

First half earnings released

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $8.196 million.